Company’s 36-month beta value is 0.83.Analysts have differing opinions on the stock, with 11 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for VYGR is 45.00M, and currently, short sellers hold a 7.11% ratio of that floaft. The average trading volume of VYGR on June 12, 2025 was 483.72K shares.
VYGR) stock’s latest price update
The stock price of Voyager Therapeutics Inc (NASDAQ: VYGR) has jumped by 4.29 compared to previous close of 3.38. Despite this, the company has seen a gain of 6.82% in its stock price over the last five trading days. globenewswire.com reported 2025-06-10 that LEXINGTON, Mass., June 10, 2025 (GLOBE NEWSWIRE) — Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today announced Alfred W. Sandrock, Jr., M.D., Ph.D., Chief Executive Officer of Voyager, and additional members of management will participate in a pre-recorded fireside chat at the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference.
VYGR’s Market Performance
Voyager Therapeutics Inc (VYGR) has experienced a 6.82% rise in stock performance for the past week, with a 7.47% rise in the past month, and a -13.28% drop in the past quarter. The volatility ratio for the week is 5.60%, and the volatility levels for the past 30 days are at 5.60% for VYGR. The simple moving average for the past 20 days is 10.11% for VYGR’s stock, with a -30.55% simple moving average for the past 200 days.
Analysts’ Opinion of VYGR
Citigroup, on the other hand, stated in their research note that they expect to see VYGR reach a price target of $12. The rating they have provided for VYGR stocks is “Buy” according to the report published on December 02nd, 2024.
Wedbush gave a rating of “Outperform” to VYGR, setting the target price at $11 in the report published on November 29th of the previous year.
VYGR Trading at 8.21% from the 50-Day Moving Average
After a stumble in the market that brought VYGR to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -63.09% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at VYGR starting from Ferguson Toby, who sale 10,086 shares at the price of $3.43 back on Apr 02 ’25. After this action, Ferguson Toby now owns 157,914 shares of Voyager Therapeutics Inc, valued at $34,595 using the latest closing price.
Sandrock Alfred, the President and CEO of Voyager Therapeutics Inc, sale 10,885 shares at $3.43 during a trade that took place back on Apr 02 ’25, which means that Sandrock Alfred is holding 430,931 shares at $37,336 based on the most recent closing price.
Stock Fundamentals for VYGR
Current profitability levels for the company are sitting at:
- -1.52 for the present operating margin
- 0.49 for the gross margin
The net margin for Voyager Therapeutics Inc stands at -1.26. The total capital return value is set at -0.33. Equity return is now at value -27.61, with -20.59 for asset returns.
Based on Voyager Therapeutics Inc (VYGR), the company’s capital structure generated 0.13 points at debt to capital in total, while cash flow to debt ratio is standing at -2.67.
Currently, EBITDA for the company is -78.56 million with net debt to EBITDA at 0.34. When we switch over and look at the enterprise to sales, we see a ratio of 2.42. The receivables turnover for the company is 31.73for trailing twelve months and the total asset turnover is 0.19. The liquidity ratio also appears to be rather interesting for investors as it stands at 6.10.
Conclusion
In a nutshell, Voyager Therapeutics Inc (VYGR) has experienced a mixed performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
